Skip to main content

Pediatric Rheum

The EMA has approved an anti-IL-6/tocilizumab biosimilar, manufactured by Fresenius-Kabi, and called Tyenne. This is the 1st TCZ biosimilar, indicated for use in RA, Systemic JIA, poly-JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome https://t.co/KGhOqmmjWe https://t.co/VGwNRSI0ls

Hard Decisions in RA (9.1.2023)

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
Gut Microbiome Differences Antedate JIA Development Researchers have shown that gut microbiome differences may be associated with later development of JIA, and that such differences are present years before the disease is diagnosed. https://t.co/MlzkzvlNoS https://t.co/nSSq50lIhS
High IL-17 levels distinguishes Kawasaki Dz from other pediatric inflammatory Dz (MIS-C, jDM, MAS, Stills, etc). IL-17 elevation seen in >50% of KD patients, including 19 of 20 with coronary artery aneurysms, but was rare in all patients. https://t.co/poKm9EEMRx https://t.co/SLKTKIS8WQ
Posthoc analysis 2 phase III RCTs of ABAtacept x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA+MTX Rx pts were compared & there were NO between group differences in efficacy (JIA-ACR & JADAS27-CRP), bio-naive vs bio-experience responses, safety & PK studies https://t.co/lBJrPzm5S1 https://t.co/RM542Hl8Fu
Comparison of 158 adults and 58 juvenile-onset Systemic sclerosis showed differences: - Time to Dx: 5 vs 2 yrs - ILD: 51% vs 30% - HTN 18% vs 0 - More limited cutaneous Dz in aSSC (74%) - More diffuse cutaneous Dz in jSSc (77%) - Higher mortality aSSC https://t.co/pMQiydwEE2 https://t.co/fNJCG4fuO9

Gut Microbiome Differences Antedate JIA Development

Aug 28, 2023

Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.

Read Article
Monoarticular JIA - a Distinct Clinical Entity Monoarticular Juvenile Idiopathic Arthritis (monoJIA) is typically classified under oligoarticular JIA, but a recent study suggests it is a separate entity. https://t.co/l5OqZsWVJi https://t.co/uR99Vs5ZNe
10% of a Single center cohort (n 38) Systemic JIA pts developed MAS. Only1 had recurrent MAS(3 times), mostly Male (3M:1F) w/ mean Dx age=8 ± 6 yrs. Stills w/ MAS had less arthritis (51 v 91%), more Rash (75 v 55%), HSM (50 v 5%), serositis (25 v 5%) https://t.co/QgdSJW03wj https://t.co/L5MTnmgWDn

Monoarticular JIA - a Distinct Clinical Entity

Aug 14, 2023

Monoarticular Juvenile Idiopathic Arthritis (monoJIA) is typically classified under oligoarticular JIA, but a recent study suggests it is a separate entity.



The analysis of 347 patients with oligoJIA, included patients with at least two years follow-up and compared oligo JIA ot mono

Read Article

Pizza and Rheumatoid Arthritis (8.11.2023)

Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:




  1. Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age

Read Article

English for the Biologically-Challenged (8.4.2023)

Aug 04, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article

Antenatal Corticosteroids and Serious Infection in Offspring

Aug 03, 2023

A claims data study shows that maternal use of antenatal corticosteroids may be associated with an increased risk of serious infection in the offspring's first 12 months. 



The study used combined, cross-referenced data from the Taiwanese National Health Insurance Research Database,

Read Article

EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

Jul 26, 2023

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to 

Read Article
MMWR: Arthritis Among Children and Adolescents The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. https://t.co/pQnB3zV7sw https://t.co/nrLZ8Uazgh
EMA's CHMP adopted a positive opinion for 1st tocilizumab biosimilar, Tyenne® (from Fresenius Kab), for Rx of RA, systemic JIA, poly JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome. No decision yet on IL6 biosimilar in USA https://t.co/w00yGfm3Vv https://t.co/UzxPvBf1nG

MMWR: Arthritis Among Children and Adolescents

Jul 21, 2023

The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. Prevalence (305 per 100,000) increased with age and is higher in 12–17 year olds; non-Hispanic Black or African Americans; those with anxiety or depression; physically inactive; overweight or a

Read Article

Anti-Drug Antibodies with Biologics (7.14.2023)

Jul 14, 2023

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article
Baricitinib Effective in JIA Subsets A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo. https://t.co/0CMzVCgsG8 https://t.co/NGE1pxsmcb

Baricitinib Effective in JIA Subsets

Jul 11, 2023

A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.

Read Article
RT @bella_mehta : An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections and other inflammatory diseases! - kids with fever! serum calprotectin (MRP8/14) particle enhanced immuno-turbidimeteic assay (sCAL Turbi). 650 pts #EULAR2023

Scleroderma – Thick and Thin (6.30.2023)

Jun 30, 2023

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
Paradoxical Psoriasis in Kids Taking TNF Inhibitors A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor. https://t.co/f1KmICaGNF https://t.co/N0jxIJbv7Q

How Often Do You Monitor MTX? (6.16.2023)

Jun 15, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. 

Read Article

Higher Genetic Loads Linked to Worse Systemic Lupus

Jun 15, 2023

A Korean study of a large systemic lupus erythematosus (SLE) cohort shows by genomic analysis, that higher weighted genetic risk scores (wGRS) is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations.



Genotyping of

Read Article
×